SCHEMBL2288552

SCHEMBL2288552

Cc1ccc(OCc2ccccc2Br)c(C)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.60
MAPT P10636 8/20 0.51
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
ALDH1A1 P00352 3/20 0.51
HTT P42858 2/20 0.51
L3MBTL1 Q9Y468 9/20 0.49
HPGD P15428 6/20 0.49
TSHR P16473 2/20 0.49
MAPK1 P28482 2/20 0.49
LMNA P02545 1/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30023195 1.00 FFAR4 (0.60) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL30000324 0.87 FFAR4 (0.50) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2290442 0.87 FFAR4 (0.50) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL13793923 0.83 L3MBTL1 (0.51) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2292785 0.83 ALDH1A1 (0.57) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL30342568 0.83 ALDH1A1 (0.57) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL8624560 0.81 L3MBTL1 (0.49) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL17616639 0.81 L3MBTL1 (0.49) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL9116732 0.81 L3MBTL1 (0.49) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2292139 0.80 THRA (0.48) FFAR4MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115243764-A Heterocyclic derivatives as TRMP8 antagonists 奇华顿股份有限公司 2022-10-25 CN disclosed
EP-2149545-B1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2016-10-05 EP disclosed
US-7994367-B2 Method for producing benzaldehyde compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20100210879-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-08-19 US disclosed
EP-2149545-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210879-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND NQO1, C9, TRPA1 FFAR4 3092/4885MAPT 3284/4885NPC1 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.